Heron Therapeutics, Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating restated by analysts at Noble Financial in a report issued on Friday, October 6th. They currently have a $24.00 price target on the biotechnology company’s stock. Noble Financial’s price target suggests a potential upside of 56.35% from the stock’s current price.
Several other equities research analysts have also commented on the stock. Northland Securities assumed coverage on shares of Heron Therapeutics in a research report on Wednesday, September 27th. They set an “outperform” rating and a $40.00 price target for the company. Mizuho assumed coverage on shares of Heron Therapeutics in a report on Tuesday, September 26th. They issued a “buy” rating and a $28.00 target price for the company. Cantor Fitzgerald reissued a “buy” rating on shares of Heron Therapeutics in a report on Monday, September 25th. BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $28.50.
Shares of Heron Therapeutics (HRTX) opened at 15.35 on Friday. The company’s 50 day moving average is $15.97 and its 200-day moving average is $15.18. The firm’s market capitalization is $831.02 million. Heron Therapeutics has a one year low of $12.21 and a one year high of $20.85.
Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. Equities analysts expect that Heron Therapeutics will post ($3.51) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was reported by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/heron-therapeutics-inc-hrtx-rating-reiterated-by-noble-financial/1697589.html.
A number of large investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC raised its holdings in Heron Therapeutics by 2.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 771 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Heron Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after purchasing an additional 1,026 shares during the period. Legal & General Group Plc increased its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,098 shares during the period. HighTower Advisors LLC increased its stake in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 1,700 shares during the period. Finally, Tudor Investment Corp ET AL increased its stake in Heron Therapeutics by 10.2% in the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after purchasing an additional 1,724 shares during the period.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with our FREE daily email newsletter.